WINTON GROUP Ltd Buys Shares of 78,072 Dyne Therapeutics, Inc. $DYN

WINTON GROUP Ltd purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the third quarter, HoldingsChannel.com reports. The fund purchased 78,072 shares of the company’s stock, valued at approximately $988,000.

Other large investors have also recently made changes to their positions in the company. Aberdeen Group plc raised its holdings in shares of Dyne Therapeutics by 15.0% during the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after purchasing an additional 72,770 shares during the last quarter. Vanguard Group Inc. grew its position in Dyne Therapeutics by 27.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares during the period. Arcadia Investment Management Corp MI grew its position in Dyne Therapeutics by 23.1% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock worth $526,000 after purchasing an additional 10,350 shares during the period. Saturn V Capital Management LP purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at $13,856,000. Finally, Squarepoint Ops LLC raised its stake in Dyne Therapeutics by 334.3% during the 2nd quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock valued at $1,730,000 after buying an additional 139,896 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Brian S. Posner acquired 3,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $15.06 per share, for a total transaction of $45,180.00. Following the purchase, the director owned 11,500 shares in the company, valued at $173,190. The trade was a 35.29% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 14.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on DYN shares. Robert W. Baird set a $30.00 price target on Dyne Therapeutics in a research note on Monday, December 8th. Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a research report on Tuesday, December 9th. Tudor Pickering set a $23.00 target price on Dyne Therapeutics in a report on Tuesday, December 9th. Chardan Capital reissued a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday. Finally, Evercore cut their price target on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $35.14.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded down $0.13 during trading on Friday, reaching $17.94. The company had a trading volume of 409,747 shares, compared to its average volume of 2,164,836. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $25.00. The firm’s 50-day simple moving average is $17.00 and its 200 day simple moving average is $17.23. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -5.08 and a beta of 1.34. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.